LYFGENIA market seen growing through 2030 on sickle cell demand

The Business Research Company says the LYFGENIA gene therapy market is expanding as sickle cell disease cases rise and demand builds for one-time, curative treatments. North America held the largest share in 2025, while the report points to broader growth across major regions through 2030.

Why it matters: - LYFGENIA is part of a wider shift in gene therapy toward one-time treatments for rare diseases, especially sickle cell disease. - The market outlook reflects rising demand for curative therapies that could reduce long-term symptoms, transfusions and ongoing chronic care. - The report frames LYFGENIA as a growth market through 2030 because sickle cell prevalence and chronic disease burdens are increasing.

What happened: - The Business Research Company published its LYFGENIA Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says LYFGENIA has grown historically on the back of higher sickle cell disease prevalence, limited effectiveness of symptom-focused chronic treatments and more specialized hematology centers. - The report says future growth should be supported by investment in rare disease gene therapy pipelines, demand for curative sickle cell treatments and new manufacturing facilities. - The report says North America held the largest share of the LYFGENIA market in 2025.

The details: - LYFGENIA is a one-time gene therapy approved for people age 12 and older with a history of vaso-occlusive events caused by sickle cell disease. - The therapy is designed to correct the genetic mutation in patients’ stem cells. - The report says that mechanism supports healthy hemoglobin production, helps prevent red blood cells from sickling and can reduce symptoms and dependence on blood transfusions. - Sickle cell anemia causes abnormal hemoglobin production, which can make red blood cells rigid and crescent-shaped. - That shape can block blood flow and lead to pain, organ damage and higher infection risk. - The disease is inherited in an autosomal recessive pattern. - The Perth Blood Institute estimated that about 275,000 babies are born each year with sickle cell disease worldwide. - The institute projects that number could exceed 400,000 by 2050. - The report says chronic health conditions are also boosting demand for LYFGENIA and similar gene therapies. - The NHS Confederation projects that nearly 17% of the UK population will be living with four or more chronic conditions by 2035. - The report lists Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa as other covered regions.

Between the lines: - The market case for LYFGENIA depends less on symptom management and more on the value of potentially curative treatment. - The report highlights a broader industry trend toward single-dose gene therapies, stem cell gene modification and personalized treatment development. - North America’s lead suggests that advanced healthcare infrastructure, gene therapy investment and patient access remain key commercial advantages. - The inclusion of TAM analysis, company scoring matrices, forecasting dashboards and updated graphics signals that the report is aimed at investors and strategists, not just clinicians.

What's next: - The report expects continued market expansion as manufacturers scale capacity and more patients seek curative sickle cell options. - Broader global access to gene-based treatments will likely shape how quickly the market grows outside North America. - The company is also offering a free sample report and full market report through its website. - More information is available in the company’s announcement and the full report.

The bottom line: - LYFGENIA’s market outlook is being driven by rising sickle cell burden, a push for curative therapies and growing confidence in gene therapy as a long-term treatment model.